Accessible Search Form           Advanced Search

Gary H. Gibbons, M.D.

To arrange an interview, please contact the NHLBI Communications Office at 301-496-4236 or nhlbi_news@nhlbi.nih.gov.

Portrait of Dr. Gibbons
Gary H. Gibbons, M.D.

High Res JPG file (5057 KB)

Biography

Gary H. Gibbons, M.D., is Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), where he oversees the third largest institute at the NIH, with an annual budget of more than $3 billion and a staff of 917 federal employees.

The NHLBI provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.

Prior to being named director of the NHLBI, Gibbons served as a member of the National Heart, Lung, and Blood Advisory Council (NHLBAC) from 2009-2012. He was also a member of the NHLBI Board of Extramural Experts (BEE), a working group of the NHLBAC.

Before joining the NHLBI, Gibbons served as the founding director of the Cardiovascular Research Institute, chairperson of the Department of Physiology, and professor of physiology and medicine at the Morehouse School of Medicine, in Atlanta.

Under his leadership of the Cardiovascular Research Institute, Gibbons directed NIH-funded research in the fields of vascular biology, genomic medicine, and the pathogenesis of vascular diseases. During his tenure, the Cardiovascular Research Institute emerged as a center of excellence, leading the way in discoveries related to the cardiovascular health of minority populations. Gibbons received several patents for innovations derived from his research in the fields of vascular biology and the pathogenesis of vascular diseases.

Gibbons earned his undergraduate degree from Princeton University in Princeton, N.J., and graduated magna cum laude from Harvard Medical School in Boston. He completed his residency and cardiology fellowship at the Harvard-affiliated Brigham and Women's Hospital in Boston. Prior to joining the Morehouse School of Medicine in 1999, Gibbons was a member of the faculty at Stanford University in Stanford, Calif., from 1990-1996, and at Harvard Medical School from 1996-1999. 

Throughout his career, Gibbons has received numerous honors, including election to the Institute of Medicine of the National Academies of Sciences; selection as a Robert Wood Johnson Foundation Minority Faculty Development Awardee; selection as a Pew Foundation Biomedical Scholar; and recognition as an Established Investigator of the American Heart Association (AHA).


Dr. Gibbons In the News

September 9, 2014
NIH-convened panel recommends expanded adoption of drug and transfusion treatments for individuals with sickle cell disease
An expert panel has recommended expanded adoption of the drug hydroxyurea for the care of people with sickle cell disease, according to a report issued today. The report also suggests that clinicians give periodic blood transfusions to children with the disease to reduce stroke risk. According to the panel, both treatments are underutilized.

April 2, 2014 : Am. J. of Respiratory and Critical Care Medicine
Developing a research agenda for primary prevention of chronic lung diseases—an NHLBI perspective
authored by James Kiley, Ph.D., director of NHLBI Division of Lung Diseases, and Gary Gibbons, M.D., director of NHLBI
The NHLBI has a long history of supporting highly productive and pivotal research that has translated into new therapies and improved management for chronic lung diseases. To date, our greatest successes have derived from research focused on the treatment of existing diseases in symptomatic patients, and there has been less research attention on primary prevention of lung diseases. We are intrigued by the promise of new insights into chronic lung disease coming from continuing advances in genetics, the blossoming field of reparative biology, and the applications of new imaging and “omic” technologies in well-characterized patients and populations. These scientific advances embolden us to envision a future in which we challenge the prevailing concept of “chronic lung disease” and contemplate the development of preventive strategies that will preempt the progression to lung disease and/or promote its “remission” toward normal lung physiology and respiratory health.

View all Dr. Gibbons in the news articles

Last Updated: August 13, 2012